» Articles » PMID: 37189118

What Are Economic Costs and when Should They Be Used in Health Economic Studies?

Overview
Publisher Biomed Central
Date 2023 May 15
PMID 37189118
Authors
Affiliations
Soon will be listed here.
Abstract

Economic analyses of healthcare interventions are an important consideration in evidence-based policymaking. A key component of such analyses is the costs of interventions, for which most are familiar with using budgets and expenditures. However, economic theory states that the true value of a good/service is the value of the next best alternative forgone as a result of using the resource and therefore observed prices or charges do not necessarily reflect the true economic value of resources. To address this, economic costs are a fundamental concept within (health) economics. Crucially, they are intended to reflect the resources' opportunity costs (the forgone opportunity to use those resources for another purpose) and they are based on the value of the resource's next-best alternative use that has been forgone. This is a broader conceptualization of a resource's value than its financial cost and recognizes that resources can have a value that may not be fully captured by their market price and that by using a resource it makes it unavailable for productive use elsewhere. Importantly, economic costs are preferred over financial costs for any health economic analyses aimed at informing decisions regarding the optimum allocation of the limited/competing resources available for healthcare (such as health economic evaluations), and they are also important when considering the replicability and sustainability of healthcare interventions. However, despite this, economic costs and the reasons why they are used is an area that can be misunderstood by professionals without an economic background. In this paper, we outline to a broader audience the principles behind economic costs and when and why they should be used within health economic analyses. We highlight that the difference between financial and economic costs and what adjustments are needed within cost calculations will be influenced by the context of the study, the perspective, and the objective.

Citing Articles

Systematic review on the cost of seasonal malaria chemoprevention (SMC).

Ruisch A, Iodice M, Mathur I, Harris S, Walker D, Owusu R Malar J. 2024; 23(1):384.

PMID: 39695670 PMC: 11657606. DOI: 10.1186/s12936-024-05217-1.


Trends and changes in the relationship between quality and price in tenders for healthcare services in the Israeli health system, 2013-2023.

Niv-Yagoda A, Goldshtein H BMC Health Serv Res. 2024; 24(1):1596.

PMID: 39695563 PMC: 11654431. DOI: 10.1186/s12913-024-11963-4.


Economic Burden of Haemophilia from a Societal Perspective: A Scoping Review.

El-Sayed A, Bolous N Pharmacoecon Open. 2024; 9(2):179-205.

PMID: 39548037 PMC: 11865401. DOI: 10.1007/s41669-024-00540-4.


The Effectiveness of Digital Health Lifestyle Interventions on Weight Loss in People With Prediabetes: A Systematic Review, Meta-Analysis, and Meta-Regression.

Fredensborg Holm T, Udsen F, Giese I, Faerch K, Jensen M, von Scholten B J Diabetes Sci Technol. 2024; :19322968241292646.

PMID: 39508277 PMC: 11571619. DOI: 10.1177/19322968241292646.


The what, the when and the how: A qualitative study of allied health decision-maker perspectives on factors influencing the development and implementation of advanced and extended scopes of practice in Australia.

Downie S, Gavaghan B, DAtri M, McBride L, Kirk-Brown A, Haines T Int J Health Plann Manage. 2024; 40(1):130-155.

PMID: 39363232 PMC: 11704828. DOI: 10.1002/hpm.3850.


References
1.
Miners A . Estimating 'costs' for cost-effectiveness analysis. Pharmacoeconomics. 2008; 26(9):745-51. DOI: 10.2165/00019053-200826090-00005. View

2.
Johns B, Baltussen R, Hutubessy R . Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc. 2003; 1(1):1. PMC: 156020. DOI: 10.1186/1478-7547-1-1. View

3.
Garrison Jr L, Mansley E, Abbott 3rd T, Bresnahan B, Hay J, Smeeding J . Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health. 2009; 13(1):8-13. DOI: 10.1111/j.1524-4733.2009.00660.x. View

4.
Culyer A . COST, CONTEXT, AND DECISIONS IN HEALTH ECONOMICS AND HEALTH TECHNOLOGY ASSESSMENT. Int J Technol Assess Health Care. 2018; 34(5):434-441. DOI: 10.1017/S0266462318000612. View

5.
Sandmann F, Robotham J, Deeny S, Edmunds W, Jit M . Estimating the opportunity costs of bed-days. Health Econ. 2017; 27(3):592-605. PMC: 5900745. DOI: 10.1002/hec.3613. View